Cellectis (CLLS) Competitors $1.54 -0.01 (-0.65%) As of 05/20/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. CKPT, SNDL, TRDA, OLMA, ARCT, HRTX, SEPN, BNTC, FULC, and ATYRShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Heron Therapeutics Septerna Benitec Biopharma Fulcrum Therapeutics Atyr PHARMA Cellectis (NASDAQ:CLLS) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Which has more risk and volatility, CLLS or CKPT? Cellectis has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Does the media favor CLLS or CKPT? In the previous week, Cellectis had 2 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 3 mentions for Cellectis and 1 mentions for Checkpoint Therapeutics. Cellectis' average media sentiment score of -0.01 beat Checkpoint Therapeutics' score of -0.33 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Checkpoint Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in CLLS or CKPT? 63.9% of Cellectis shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CLLS or CKPT more profitable? Checkpoint Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Checkpoint Therapeutics' return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-234.39% -74.55% -22.65% Checkpoint Therapeutics N/A N/A -659.07% Does the MarketBeat Community believe in CLLS or CKPT? Cellectis received 233 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. However, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 65.05% of users gave Cellectis an outperform vote. CompanyUnderperformOutperformCellectisOutperform Votes41565.05% Underperform Votes22334.95% Checkpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Do analysts prefer CLLS or CKPT? Cellectis currently has a consensus target price of $6.67, indicating a potential upside of 332.90%. Checkpoint Therapeutics has a consensus target price of $4.33, indicating a potential upside of 4.17%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger valuation & earnings, CLLS or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Cellectis. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$47.63M1.80-$101.06M-$0.86-1.79Checkpoint Therapeutics$41K8,498.98-$51.85M-$1.29-3.22 SummaryCellectis beats Checkpoint Therapeutics on 13 of the 18 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.60M$2.97B$5.43B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.1831.5826.8220.05Price / Sales1.80414.63393.28116.44Price / CashN/A168.6838.2534.62Price / Book1.013.376.874.61Net Income-$101.06M-$72.17M$3.22B$248.19M7 Day Performance11.59%18.10%6.81%2.97%1 Month Performance11.59%20.85%13.71%16.58%1 Year Performance-47.80%-24.45%18.30%8.16% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis2.7573 of 5 stars$1.54-0.6%$6.67+332.9%-48.1%$85.60M$47.63M-1.18290CKPTCheckpoint Therapeutics1.9501 of 5 stars$4.16-0.2%$4.33+4.2%+104.9%$348.46M$41,000.00-2.2610News CoveragePositive NewsSNDLSNDL3.1518 of 5 stars$1.32+2.3%$3.63+174.6%-44.6%$346.86M$927.61M-4.26580News CoveragePositive NewsTRDAEntrada Therapeutics2.9615 of 5 stars$8.82+5.3%$25.67+191.0%-46.2%$334.75M$172.22M5.55110Analyst ForecastOLMAOlema Pharmaceuticals2.3112 of 5 stars$4.76+3.5%$27.67+481.2%-46.6%$325.40MN/A-2.1770Positive NewsGap UpARCTArcturus Therapeutics2.9697 of 5 stars$11.59+5.6%$59.20+410.8%-58.4%$314.33M$138.39M-5.22180Gap UpHRTXHeron Therapeutics3.9182 of 5 stars$2.05-2.8%$5.50+168.3%-43.5%$312.76M$148.52M-11.39300Positive NewsSEPNSepterna2.0964 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportBNTCBenitec Biopharma2.4448 of 5 stars$13.14-3.6%$24.71+88.1%+33.0%$308.15M$80,000.00-8.7020News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics0.7716 of 5 stars$5.68+5.8%$8.63+51.8%-15.5%$306.60M$80M-18.32100ATYRAtyr PHARMA2.8502 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies CKPT Alternatives SNDL Alternatives TRDA Alternatives OLMA Alternatives ARCT Alternatives HRTX Alternatives SEPN Alternatives BNTC Alternatives FULC Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
